Alder Biopharmaceuticals Announces Expanded Collaboration with Schering-Plough
News Jun 09, 2009
Alder Biopharmaceuticals, Inc. has announced the expansion of its collaborative alliance with Schering-Plough Corporation. The collaboration continues to be successful in identifying numerous high quality therapeutic monoclonal antibody lead candidates.
Candidates with potential applications to Central Nervous System (CNS) disorders are being identified through the application of Alder’s high throughput antibody selection (ABS) system and yeast production system (Mab Xpress). These technologies are designed to identify and produce best-in-class antibodies.
Under terms of the agreement, Alder will receive an upfront payment, committed funding for Alder personnel who are engaged in the project and milestone payments associated with the advancement of a therapeutic candidate as well as future product royalties.
“This expanded collaboration further validates the promise and potential of Alder’s leading capabilities to expeditiously identify and manufacture therapeutic monoclonal antibodies,” said Randall Schatzman, Ph.D., Chief Executive Officer of Alder. “We look forward to the continued and expanded partnership with Schering Plough, a leader in therapeutic antibody development and commercialization. More broadly, we are pleased to be positively impacting the way in which companies discover and manufacture biotherapeutics.”
Worms Exhibit Fear and Respond to Anti-anxiety MedsNews
A team of investigators has uncovered new clues about the mechanisms of fear and anxiety through an unlikely creature: the tiny nematode worm.READ MORE
Low Temperatures Turn Stem Cells into Calorie-Burning FatNews
The secret to healthy eating may not be in freezer food, but low temperatures can help turn stem cells into brown fat, a type of fat which helps burn calories. A new study could turn this knowledge into weight-loss treatments.READ MORE